Memo Therapeutics AG Appoints Erik van den Berg as Chief Executive Officer

16 Nov 2023
www.biospace.com
Executive ChangeFast Track
Mr. van den Berg is an industry veteran with proven track record in building high-performance teams and delivering on strategic and financial transactions ZURICH--(BUSINESS WIRE)-- Memo Therapeutics AG (“MTx”), a late-stage biotech company developing best-in-class therapeutic antibodies, announced today the appointment of Erik van den Berg as Chief Executive Officer (CEO). This press release features multimedia. View the full release here: Erik van den Berg, CEO of Memo Therapeutics AG (Photo: Business Wire) Mr. van den Berg joins MTxMTx with over 25 years’ industry experience and proven track record in leading and growing companies. During his career, Mr. van den Berg has successfully completed over 20 transactions and partnerships, including a $600 million alliance with Pfizer, $290 million partnership with Kyowa Kirin and $500M in equity and debt financings for biotechnology companies from seed through IPO. He succeeds Dr. Karsten Fischer, who stepped down to pursue other opportunities. “As Memo continues to make progress to address unmet medical needs of patients, Erik is the perfect person to lead the company through late-stage clinical development and towards potential commercialization of our lead program, AntiBKV. On behalf of the Board and entire team, I’d like to welcome Erik to MTxMTx and look forward to our future endeavors,” said Elias Papatheodorou, Chairman of MTxMTx’s Board of Directors. “I’d also like to thank Dr. Karsten Fischer who served as our CEO for the past 5 years for his dedication and leadership in taking our technological approach into the clinic with multiple antibody candidates.” Mr. van den Berg was CEO of AM-Pharma for over 12 years and remains on its Board. He is also Chairman of Step Pharma, TargED Therapeutics, co-founder and previous (executive) Chairman of Lava Therapeutics and co-founder and previous (executive) Chairman of Heatmatrix Group (sold to BosNieuwkerk). Previously, Mr. van den Berg also held business development roles at Organon and IsoTis (sold to Integra Lifesciences). Mr. van den Berg holds a master’s degree in chemistry from the University of Utrecht and an MBA from Manchester Business School. “Memo has already made great strides in its development of novel antibody candidates. As CEO, I look forward to continuing this momentum and build on the great progress made recently with AntiBKV in the clinic and its Fast Track designation from the FDA, as well as the recent successful Series C fundraising,” said Mr. van den Berg. About Memo Therapeutics AG Memo Therapeutics AG (“MTx”) is a late-stage biotech company developing best-in-class therapeutic antibodies to transform the lives of patients with virus infections and cancer. MTxMTx’s lead program, AntiBKV, is a highly effective and safe neutralizing antibody to treat BK virus infection in kidney transplant recipients. This infection can lead to loss of kidney function, as well as organ failure and rejection. MTx’s pipeline consists of additional candidate therapeutic antibodies focusing on infectious diseases, such as cytomegalovirus (“CMV”), immuno-oncology targets as well as a partnership with Ono Pharmaceutical. MTxMTx is a private company located in Schlieren / Zurich, Switzerland. View source version on businesswire.com: Contacts Memo Therapeutics AG info@memo-therapeutics.com Halsin Partners Mike Sinclair +44 (0) 7968 022075 msinclair@halsin.com Source: Memo Therapeutics AG Smart Multimedia Gallery Photo Erik van den Berg, CEO of Memo Therapeutics AG (Photo: Business Wire) Logo View this news release and multimedia online at:
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-
Drugs
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.